Complement dependent cytotoxicity (CDC) activity of a humanized anti Lewis-Y antibody: FACS-based assay versus the ‘classical’ radioactive method—Qualification, comparison and application of the FACS-based approach

This publication has 14 references indexed in Scilit:

• Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family
  International Immunopharmacology, 2005
• Characterizing biological products and assessing comparability following manufacturing changes
  Nature Biotechnology, 2004
• Tumor necrosis factor-α blockade for the treatment of acute GVHD
  Blood, 2004
• Complement function in mAb-mediated cancer immunotherapy
  Trends in Immunology, 2004
• Antibodies Directed against Lewis-Y Antigen Inhibit Signaling of Lewis-Y Modified ErbB Receptors
  Cancer Research, 2004
• Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
  The Journal of Immunology, 2003
• The mechanisms of action of rituximab in the elimination of tumor cells
  Seminars in Oncology, 2003
• Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1
  Journal of Virology, 2001
• High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR
  Journal of Biological Chemistry, 2001
• A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity
  Journal of Immunological Methods, 1988